Your session is about to expire
← Back to Search
Observational (blood collection) for Testicular Cancer
N/A
Recruiting
Led By Craig R Nichols
Research Sponsored by SWOG Cancer Research Network
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights
Summary
This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back.
Eligible Conditions
- Testicular Cancer
- Germ Cell Tumors
- Malignant Neoplasm
- Seminoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
To bank blood specimens of patients at low risk and moderate risk of relapse
To estimate positive predictive value of miRNA 371 in early stage testicular seminoma and nonseminoma patients
Trial Design
1Treatment groups
Experimental Treatment
Group I: Observational (blood collection)Experimental Treatment2 Interventions
Patients undergo collection of blood every 3-6 months for up to 3 years.
Find a Location
Who is running the clinical trial?
SWOG Cancer Research NetworkLead Sponsor
395 Previous Clinical Trials
264,192 Total Patients Enrolled
Southwest Oncology GroupLead Sponsor
388 Previous Clinical Trials
260,305 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,748 Previous Clinical Trials
40,958,445 Total Patients Enrolled
5 Trials studying Testicular Cancer
65,613 Patients Enrolled for Testicular Cancer
Share this study with friends
Copy Link
Messenger